Substance / Medication

Rifabutin

Overview

Active Ingredient
rifabutin
RxNorm CUI
55672
Labeler: RedHill Biopharma LtdUpdated: 2025-12-23T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Association between the rifampicin resistance mutations and rifabutin susceptibility in Mycobacterium tuberculosis: A meta-analysis.
Wang Wenli, Zhou Hongjuan, Cai Long et al. · J Glob Antimicrob Resist · 2025
PMID: 39617268Meta-Analysis
Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review.
Xirouchakis Elias, Georgopoulos Sotirios D · Expert Opin Pharmacother · 2022
PMID: 34595999Meta-Analysis
Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
Gingold-Belfer Rachel, Niv Yaron, Levi Zohar et al. · J Gastroenterol Hepatol · 2021
PMID: 33037845Meta-Analysis
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
Whitfield Michael G, Warren Robin M, Mathys Vanessa et al. · J Antimicrob Chemother · 2018
PMID: 29982641Meta-AnalysisFull text (PMC)
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma Surendra K, Sharma Anju, Kadhiravan Tamilarasu et al. · Cochrane Database Syst Rev · 2013
PMID: 23828580Meta-AnalysisFull text (PMC)
Rifabutin for treating pulmonary tuberculosis.
Davies G, Cerri S, Richeldi L · Cochrane Database Syst Rev · 2007
PMID: 17943842Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rifabutin (substance)
SNOMED CT
386893001
UMLS CUI
C0140575
RxNorm CUI
55672
Labeler
RedHill Biopharma Ltd

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.